Media stories about Chemed (NYSE:CHE) have trended somewhat positive on Thursday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chemed earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.226469344699 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Chemed (CHE) traded down $0.32 during midday trading on Thursday, reaching $259.73. 78,600 shares of the company’s stock were exchanged, compared to its average volume of 99,157. Chemed has a one year low of $161.48 and a one year high of $261.91. The firm has a market capitalization of $4,100.00, a price-to-earnings ratio of 57.85, a PEG ratio of 2.87 and a beta of 1.16. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping the consensus estimate of $2.00 by $0.15. Chemed had a net margin of 8.49% and a return on equity of 30.54%. The firm had revenue of $417.40 million during the quarter, compared to analyst estimates of $414.34 million. During the same quarter in the prior year, the business posted $1.73 earnings per share. Chemed’s revenue for the quarter was up 6.3% compared to the same quarter last year. research analysts anticipate that Chemed will post 4.73 EPS for the current year.
A number of equities analysts have recently issued reports on CHE shares. Zacks Investment Research downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Wednesday, September 13th. Royal Bank of Canada reissued a “hold” rating and issued a $209.00 target price on shares of Chemed in a research report on Tuesday, October 3rd. KeyCorp reissued a “hold” rating on shares of Chemed in a research note on Friday, October 27th. Oppenheimer raised their price target on shares of Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Finally, TheStreet raised shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Chemed has a consensus rating of “Hold” and an average price target of $236.00.
In related news, insider David Patrick Williams sold 11,000 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the transaction, the insider now owns 74,857 shares in the company, valued at approximately $18,061,496.96. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin J. Mcnamara sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total transaction of $2,234,200.00. Following the transaction, the chief executive officer now owns 170,016 shares in the company, valued at approximately $37,984,974.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 45,679 shares of company stock worth $10,628,959. Corporate insiders own 4.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/chemed-che-earning-somewhat-positive-news-coverage-study-finds.html.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.